International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

A Review on Weight Gain Associated With Antipsychotic Usage and Management of the Same In Order To Avoid Patients Non-Complaince

Ponraj N[1*], Santhosh S[1], Thenmozhi P.M[1] , Dr. Thirupathy kumaresan .P[2]
[2] *Professor, Department of pharmacology, Arulmigu kalasalingam college of pharmacy, Krishnankoil, Virudhunagar, Tamil Nadu, India-626126.*
[*1] *5th Year of Doctor of Pharmacy, Arulmigu kalasalingam college of pharmacy, Virudhunagar, Tamilnadu, India – 626126.*
Address of correspondence: *Mr.N. Ponraj, Doctor of pharmacy, Arulmigu kalasalingam college of pharmacy, Krishnankoil, Virudhunagar, Tamilnadu, India – 626126.*

Submitted: 01-03-2022 Accepted: 13-03-2022

ABSTRACT:
The Antipsychotic cause weight gain is a significant administration issues for clinicians. It has been indicated that weight gain and corpulence lead to expanded cardiovascular and cerebrovascular dismalness and mortality, diminished personal satisfaction and helpless medicationconsistence.Weightgainbuildsthedanger ofmetabolicsicknesses.Weightincrements quickly in the underlying time frame in the wake of beginning antipsychotics. The danger gives offanimpressionofbeingmostelevatedwitholanzapin eandclozapine.Theorderlyauditexamine the inclination of different antipsychotic to cause weight gain and lessening persistent adherence. The pharmacologic and non pharmacologic intervention accessible to forestall this impact and its effect on adherence. Metformin has the best proof in this regard. Weight of results should be viewed as when endorsing weight reduction meds. There is no solid proof to suggest routine remedy of extra medicine for weight decrease. Heterogeneity of study strategies and other confounders, for example, way of life, hereditary and ailment factors make understanding of informationtroublesome.

Key words: Atypical antipsychotics, Olanzapine, Weight gain, Patient adherence,weight reducing agents

I. INTRODUCTION:

Antipsychotic medication are basically shown for the treatment of schizophrenia and other psychotic problems (comprise schizoaffective disorder, delusional disorder and bipolar affective disorder BPAD) they have generally been arranged as first generation (once known as 'typical' or 'conventional') antipsychotics (FGAs) or second generation antipsychotics (SGAs) (formerly 'atypical antipsychotics). The weight of results related with FGAs, specifically crippling extrapyramidal side effects(EPSEs), lead to the presentation of the SGA medication during the 1990s.TheSGAshavealoweraffinitytocauseEPSEs,(forexampleintensedystonias,akathisia, parkinsonismandtardivedyskinesia)contrastedandth eFGAs,andtheseproperties,linedupwith theirseparatingreceptorsprofiles,driventhemtobena medas'atypical'.[1]The8SGAsthatareas of now authorized for use in the UK (12 altogether are authorized in Europe) were displayed on thepharmacologicalprofileofclozapine,becauseofitsl owtendencytocauseEPSEsandsuperior effectivenessinrefractoryschizophrenia.[2]Inthisrevi ewwewillhighlighttheshortandlongterm effectofbodyweightduetotheconsumptionofantipsyc hoticdrugswiththefocusSGAsusedfor severalindications.

MECHANISM OF WEIGHT GAIN AND OTHER METABOLIC ABNORMALITIES CAUSED BY ANTIPSYCHOTICS:

Numerous system have been proposed to clarify the weight gain affinity of antipsychotics. Measure of weight gain differs with the sort of antipsychotic and the individual patient qualities. Mostexaminationhasfascinatedonclozapineandolan zapine,thetwodrugsdistinguishedtocause

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

the most noteworthy weight gain. The high probability of weight gain with these drugs has been connected to their activities at serotonin 5-HT2A and 5-HT2C, dopamine D2 and D3, histamine H1 and muscarinic M3 receptors.[3] The differential impacts on weight have been clarified bythe contrasting partiality of prescriptions at these receptors.[4,5] Antipsychotics influence neuropeptidesrelatedwithappetitecontrolandenergy metabolism.Leptinandadiponectinarethe adipokines created in white fat tissue, which have been embroiled in AIWG. Expanded leptin levels and diminished adiponectin levels have been exhibited with present moment and long term olanzapine treatment.[6,7] Ghrelin, which follows up on the arcuate core of the hypothalamus to upgrade food consumption and fat tissue deposition, is additionally influenced by antipsychotics. The progressions in leptin, adiponec¬tin and ghrelin levels have been hypothesized to be because ofdirectimpactsofthemedicationinsteadofbeingauxiliarytoweightgain.[8]Thenagain,impacts of antipsychotics on lipid and glucose metabolism have been connected with their impact on weight gain and adiposity, prompting insulin obstruction and ensuing expanded arrival of fatty substances and extremely low thickness lipoproteins from adipocytes.[9,10] A new meta-analysis by Zhang et al identified 13 single-nucleotide polymorphisms from nine genes essentially connected with AIWG.[11] Single-nucleotide polymorphisms related to ADRA2A,DRD2,5-HTR2CandMC4Rgenesshowedthelargesteffectsize, indicatingthatcandidategenesforweight gain are also linked to receptors by which antipsychotics exert their therapeuticeffects.

TIMELINE FOR WEIGHT GAIN:

There is fast weight gain in the initial not many weeks subsequent to commencing antipsychotics. The pace of weight gain then bit by bit diminishes and levels more than a while.Time taken to level was different for each antipsychotic, going from 4 to 9 months for olanzapine and from 42 to 46 months for clozapine. This demonstrates that patients would keep onputtingonweightfor1–4years.Itisreliablyannouncedthatpatientskeeponputtingonweight overtime.[12,13]AfascinatingfindingdepictedbyBaketalwasthatweightexpandedallthemore fundamentally during the period past 38 weeks than inside the initial a month and a half for olanzapine and FGA gathering and for olanzapine alone in antipsychotic-credulous group.[14] Factors related with quick weight acquire in the underlying time frame were more youthful age, lowerbenchmarkweightfile(BMI),moreheartyreactiontoantipsychoticandenhanceinappetite. Fastweightgainofover5%intheprincipalmonthisthebestindicatorforcriticallonghaulweight gain.[15]

THE ATYPICAL ANTIPSYCHOTICS INDUCE WEIGHT GAIN IN CHILDREN AND ADOLESCENT:

Despite the fact that the exact etiology is inadequately perceived, SGAs are related with incited weight gain, adipose tissue aggregation, and metabolic adverse effects. Weight gain is somewhat intense, with a huge increment as a rule seen inside 12 weeks of commencement of therapy.[16,17]Notwithstanding, the degree of the weight gain shifts between people; some put on altogether more weight than others.[16] Weight and fat addition may in the long run lead to metabolic condition and type 2 diabetes, showed by insulin opposition, glucose bigotry, dyslipidemia and hypertension, and an expanded danger for cardiovascular ailment.[18-20] The danger of weight gain is higher in little youngsters than teenagers and youthful grown-ups.[21,22]ExtraindicatorsofSGA-incitedweightgainincorporaterecentlystartedtreatment,highdose,long term medication, utilization of clinical cannabis during SGA treatment, and low body mass index (BMI) at the start of treatment.[23] Curiously, not all patients experience the ill effects of SGA- induced weight gain in a similar way, proposing that extra factors may decide weakness [16]. Studies researching sex subordinate metabolic impacts of olanzapine and other SGAs were uncertain; most examinations found the commonness of SGA-induced weight gain to be more noteworthy in females than males, and characterized low-BMI youthful females as an in danger bunch for this unfriendly impact of SGAs, however a few investigations didn't discover this connection with sexual orientation.[24,25] Pramyothin and Khaodhiar[26] exhibited that SGA-induced weight gain is brought about by expanded food utilization and the medications' solid impact on eating conduct, instead of diminished energy consumption. Likewise, various examinations have indicated expanded caloric admission and craving in patients getting SGA treatment.[27] Nonetheless, additional mechanisms, including moderate metabolic rates, have additionally been recommended.[28] It has been found in the two youngsters and grown-ups that the SGAs

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

olanzapine and clozapine have the principle sway on weight acquire, while risperidone and quetiapine have a lesser effect, aripiprazole is extensively more powerless, and ziprazidone has negligible effect on weight acquire.[16,21,29,30]

SGAs CAN CAUSE METABOLIC SIDE EFFECTS SUCH AS CARDIAC AND DIABETIC DISEASE:

As referenced before, another concerning issue while taking SGAs is the higher likelihood of creating type 2 diabetes, particularly among the pediatric population.[31] Studies indicated that SGAs lead to diminished insulin discharge and less viable glucose metabolism. Surely, glucose levelswereraisedinthewakeoftakingafewsortsofSGAdrugs.[32]Inacorrelationofkidsaged 9–18 taking SGAs furthermore, drug gullible kids, the insulinogenic index and insulin sensitivity index-2 was a lot of lower in quetiapine treated youngsters contrasted with the native group.[33] Studies in mice demonstrated comparable outcomes, however just with clozapine.[34] While a portionofthemetabolicimpactsidentifiedwithSGAs mightbeauxiliarytoweightgain,examines show that SGAs additionally have direct impacts on insulin resistance and glucose dysregulation thatarefreeofweightgain,andevenofmentalmorbidity.[35]IthasbeenrecommendedthatSGAs may expand the danger for heart sickness (e.g., cardiovascular arrhythmia and acute coronary syndrome).[36,37] In patients with schizophrenia, it has been demonstrated that taking SGAs conceivably causes a raised danger of acute coronary syndrome, especially toward the beginning oftreatment.[38]Also,inameta-examinationof176reportsofSGAresults,heartabnormalities(e.g., cardiac arrhythmias, prolonged QT intervals and orthostatic hypotension) saw in electrocardiograms were found to be moderately normal results.[36] An expanded danger for ventricular arrhythmia has likewise been related with the utilization of antipsychotic drugs . Such clinical appearances may be a serious danger factor for abrupt heart death.[37] Nonetheless, these discoveries stay disputable on the grounds that numerous examinations have discovered no impacts of SGAs parameters, such as QTc [39], explicitly in youngsters and teenagers.[40] When testingtherateofmajorcardiovascularoccasions,some antipsychoticregimensseemedtoexpand occurrence, in spite of the fact that this was generally in more established grown-up patients.[41]

CLINICAL FEAUTURES AND PREDICTORS OF BODY WEIGHT GAIN:

Afewinvestigationsfoundthattheextentofbodyweightgaincorrespondedconverselywith the age and with the body mass index (BMI) before treatment, associated emphatically with the clinicalreactiontoandhadalltheearmarksofbeingmoreenoteworthyinwomenthanBodyweight Gaininmen.[42-45]Otherexaminationsdidn'tlocatesimilarimpactofsexualorientationandbasal BMI. A positive relationship between olanzapine dose and bodyweight gain was at firstreported,[46] yet it has not been reliably replicated.[47] In one investigation with olanzapine, plasma drug concentration ³20.6 ng/mL were related with huge bodyweight gain.[48] With risperidone, chime formed and direct connections were observed,[49,50] though quetiapine indicated a bimodal example, with doses going from <200 mg/day to >600 mg/day.[51] It has been contended that in many examinations drug dosage are lower than those utilized in clinical practice; subsequently, this hampers the capacity to make distinct inferences on these relationships.The bodyweight gain timecoursehasadditionallybeenhardtodetermine.[52] Witholanzapine,bodyweightgainwillin general level off around the 39th week of treatment,[47] while with clozapine bodyweight gain proceeds past 46 weeks.[53] With risperidone, the bodyweight gain perseveres for >6 months, [54]however may arrive at a level with quetiapine as right on time as week 12[51,55]. These inconsistencies are probably related to genetic differences in bodyweight regulation amongpsychiatricpatients.Inadditionthesepredictors maybedifferentformetaboliceffects,suchasthe incidence of type 2 diabetes mellitus.[56]

WEIGHTMANAGEMENT:

Non-pharmacologicaloption:

Studiestodecideprotectedandviablemethodsforweightcontrolinpatientstakingantipsychotics have been present moment and included little quantities of overwhelmingly male patients. Nonpharmacologic strategies incorporate training; a low-calorie, low-fat eating regimen; and commitment in a weight the executives program.[57] Although these changes are viewed as the best methods for weight reduction in obese adults, similar techniques may not be appropriate to thementalpopulation.[58]allinall,selfreferred,nonpsychotic,exceptionallymotivatedpatients

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

play a more dynamic job in their medical care and are effective. Be that as it may, long term adherence to conduct changes and the attainability of close weight observing might be troublesome. Agreement board proposals with respect to weight gain incorporate the accompanying: emotional wellness suppliers screen and graph the BMI of each patient at each visit, paying little heed to the antipsychotic endorsed; the overall danger of weight gain ought to be a thought in medication choice for patients who have a BMI of 25 or higher; and except if a patient is underweight, a weight gain of one BMI unit demonstrates the requirement for a mediation, as verified previously. An intercession should start if the patient's midriff boundary is 35 inches or more prominent for a lady and 40 inches for a man.[59] Another agreement board proposal recommends including relatives, parental figures, and a medical care proficient or program with ability in weight management.[60] The patient's weight ought to be reconsidered at 4, 8, and 12 weeks in the wake of starting or changing antipsychotic treatment and quarterly from that point. They additionally express that if the patient increases 5% or a greater amount of their underlying load whenever during treatment, at that point the medication portion ought to be tightened and the medication exchanged.

Pharmacological option:

A variety of pharmacologic agents have been used (with questionable success) to counteract weightgaininducedbytheatypicalantipsychotics.Limitedevidencesuggeststhatthehistamine2- receptor antagonist-nizatidine, famotidine, and ranitidine - reverse atypical antipsychotic–induced weightgainbytargetingleptinlevels.[61]Arandomized, double-blind,placebo-controlled,8-week study involved 35 patients who had used olanzapine for the previous 3 months.[62]Nizatidine 150 mg twice/day resulted in a 4.5-kg weight loss. Leptin levels declined significantly in the active treatment group but increased in the placebo group and correlated with the change in weight and BMI in those treated with nizatidine. Amantadine, an N-methyl-D-aspartate receptor antagonist, may decrease appetite through its dopaminergic anorexic effects. Amantadine 100–300 mg/day wasstartedin12patientswithschizophreniaorbipolardisorderandameanweightgainof7.3kg duringlessthan1yearofolanzapinetreatment.Thepatients'weightsstabilizedwithamantadine and over 3–6 months they lost an average of 3.5 kg. In both the nizatidine and amantadine,reports,[62,63] no clinical deterioration occurred and no adverse effects were reported. However, the possibilitythatamantadinemayexacerbatepsychoticsymptomsinindividualswithschizophrenia makesitasecondarychoiceatbest.Theanticonvulsantopiramatemayinduceasignificantdegree of weight loss in patients with epilepsy and those treated with atypical antipsychotics. The mechanism for weight loss has not been clearly described; however, decreased intake of nutrition and increased resting energy expenditure have been reported in animal models.[64] A positive effect was demonstrated in a 12-week, randomized, placebo-controlled prospective study involving 66 inpatients taking a variety of atypical antipsychotics.[65] A daily dose of topiramate 200 mg resulted in a mean 5.35-kg weight loss, while BMI and waist and hip measurements also decreasedsignificantly.Adverseeffectswerereported asmildtomoderate,with59%experiencing paresthesias. Given its known stimulation of serotonin receptors and associated adverse effectof weightloss,theantidepressantfluoxetinehadbeenhypothesizedtobeusefulinattenuatingweight gain in patients taking olanzapine. One study included 30 patients who had been treated with the antipsychotic for less than 4 months.[66] They received either adjunctive fluoxetine 20 mg/day or placebo. After 8 weeks, the mean weight gain was 7.9 kg in the fluoxetine group, comparedwith6.0 kg in those taking placebo. Six patients withdrew from the study due to lack of treatment response or an exacerbation of psychosis. The effectiveness of sibutramine, a serotoninnorepinephrine reuptake inhibitor, was examined in 37 overweight and obese subjects taking stable doses of olanzapine.[67] In the 12-week, doubleblind, randomized, fake treatment controlled examination, subjects got fake treatment or sibutramine up to 15 mg/day and took an interest in week by week bunch meetings zeroed in on sustenance and conduct alteration. The sibutramine group had significantly greater losses than the placebo group in weight, waist circumference, BMI, and hemoglobin A1c (A1C). No huge contrasts were noted in most antagonistic impacts, albeit the sibutramine bunch showed a mean expansion in systolic pulse, anticholinergic unfavorable impacts, and rest aggravations. Orlistat lacks a centrally acting mechanism, as it blocks the absorption of ingested fat by inhibiting pancreatic lipase within the intestinal lumen. Orlistat was prescribed as adjunctive therapy for 16 weeks in a randomized, doubleblind,placebo-controlledclinicaltrialto63patientswhowerereceivingstableclozapineor olanzapine and no special

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

diet.[68] Orlistat 120 mg or placebo was administered 3 times/day. Although no statistically significant effect was observed in the whole population, male patients benefited from treatment with orlistat, losing a mean of 2.36 kg versus 0.62 kg with placebo. Adverse effects occurred in both groups; however, four patients in the orlistat group discontinued therapy because of diarrhea. Finally, modafinil, an agent approved for narcolepsy and an histamine1-agonist, was investigated for treatment of weight gain due to olanzapine use.[69] Modafinil 200 mg/day was used in a 3-week, randomized, double-blind, placebo-controlled trial in 50 healthy volunteers. Participants ate standardized breakfast and lunch only and reported on food intake, hunger, and satiety. The mean increase in BMI among those taking olanzapine and placebo was 0.89 versus 0.47 kg/m2 in those taking modafinil and olanzapine, a statistically significant difference. Adverse events were notreported.

METFORMIN:

Metformin is an antihyperglycemic agent which has been being used for a long time. It appliesits activitybyhinderinghepaticgluconeogenesisandimproving theaffectabilityofinsulininskeletal muscles through adenosine monophosphate kinase.[70] It additionally diminishes low-thickness lipoprotein cholesterol and triglycerides.[71] The fundamental component of weight reduction might be by decrease of insulin opposition and concealment of appetite.[72] Increased degree of glucagon-like peptide-1 (GLP-1) may contribute. A meta-analysis by Mizuno et al demonstrated a mean contrast of -3.17 kg (95% CI: - 4.44 to - 1.90 kg) in the metformin bunch contrasted with placebo.[73]IndividualRCTshaveindicatedthatthefaketreatmentbunchputsonweightoverthe long haul, while the metformin-treated gathering had shed pounds. A new meta-investigation of 12examinationsrevealeda-3.27kg(95%CI:-4.66to-1.89)meanchangeinweightamongmetformin and placebo.[74] The portion utilized in the preliminaries went from 750 to 1,500 mg/day.

POSSIBLITYOFANTIPSYCHOTICTOCAUSE WEIGHTGAIN:

Interestinantipsychoticscausingweightgain wasstirredafterthemilestoneconcentrateby Allison et al. This was the first meta-anlysis regarding the matter. The investigation assessed weight gain because of both first-and second-generation antipsychotics (FGAs and SGAs, individually) at standard portions for 10 weeks. Patients on fake treatment seemed to have shed pounds, while the greater part of the antipsychotics caused weight gain. A mean weight reduction of 0.39 kg was accounted for molindone, while clozapine, olanzapine, thioridazine, sertindole, chlorpromazineandrisperidoneweretotallyansweredtocausehugeweightgainfluctuatingfrom 4.45 to 2.10 kg.[75] Subsequent meta-investigations have affirmed these findings.The different medicines meta-examination by Leucht et al utilizing 6-week information detailed that all antipsychotics with the exception of haloperidol, lurasidone and ziprasidone caused weight gain.[76] Olanzapine and zotepine caused altogether more weight gain than most different antipsychotics.Anothernoholdsbarredmeta-examinationrevealedthatolanzapineandclozapine causethemostnoteworthymeasureofweightacquire,whilequetiapine,risperidoneandsertindole causedmiddlesums.Middleoftheroadtolowdegreeofweightacquirewasseenwitharipiprazole andamisulpiride.Ziprasidonecausedminimalmeasureofweightgain.[77]Ameta-investigationby De Hert et al saw that the more current antipsychotics asenapine, iloperidone, paliperidone and lurasidone caused critical weight gain. Clinically huge weight gain of over 7% was broughtabout by all the medications aside from lurasidone.[78] A new meta-analysis by Bak et al included randomized controlled preliminaries (RCTs) and controlled preliminaries distributed after 1999, regardless of diagnosis.[79] Except for aripiprazole, amisulpride and ziprasidone, most antipsychoticsincludingFGAsdemonstratedhugeweightgain.Comparableoutcomeswerefound in antipsychotic-innocent gatherings, where critical weight acquire was noticed in any event, duringtheinitialamonthandahalf.Extentofpatientswithclinicallycriticaladditionofover7% of pattern weight expanded after some time for all antipsychotics. Strangely, a critical extent of patients likewise indicated a clinically huge loss of over 7% of gauge weight with amisulpride, aripiprazole, asenapine, olanzapine, paliperidone and ziprasidone. In patients introducing in the main scene psychosis, Tek et al detailed 3.22 kg of weight gain for the time being and 5.3 kg acquire in the long haul, contrasted with placebo [80].This investigation recreated the discoveries of Leucht et al.[76]

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

PHARMACOLOGICAL INTERVENTION OF AIWG:

A few RCTs, meta-analysis and fundamental surveys have evaluated the adequacy of pharmacologic interventions in overseeing AIWG. Be that as it may, the proof for routine utilization of pharmacologic adjuvants isn't solid. A meta-analysis of RCTs of conduct and pharmacologic mediations announced that transient humble weight reduction is conceivable withnonpharmacologic and particular pharmacologic interventions.[81] A meta-examination of 40 preliminaries detailed that metformin was the most widely considered drug. It was seen that adjunctive prescriptions were started all the while with antipsychotics in 13 examinations (26%). The adjunctive treatment for weight acquire was generally started when nonpharmacologic mediations alone were not adequate or unreasonable and exchanging antipsychotics was not practicable.[82] Metformin has the most proof of viability, while topiramate, sibutramine, aripiprazole and reboxetine are additionally effective.[83,82] These medications forestall or treat weightgainthroughvariousmechanis,.Forinstance,metforminandrosiglitazoneimproveinsulin obstruction, while aripiprazole, metformin and sibutramine decline lipid levels. Different medications examined are ephedrine, orlistat, nizatidine, cimetidine, naltrexone, amantadine, reboxetine, fluoxetine, dextroamphetamine, d-fenfluramine, famotidine, fluvoxamine, phenylpropanolamine androsiglitazone.

ANTIPSYCHOTIC SWITCHING:

Antipsychotic switching is one procedure that can be utilized to diminish weight. Drug switching ought to be done after cautious thought of the danger of backslide and this ought to be done in discussion with the patient. The chance of causing more weight gain should likewise be viewed as whenswitching drug. Haloperidol, lurasidone, ziprasidone, aripiprazole and amisulpirideareviewedasthemostidealalternativesas perprooffrommetaanalyses.[84,85]There is restricted information from RCT with respect to adequacy of switching antipsychotics to improve AIWG. A Cochrane Review of four RCTs revealed a mean weight reduction of 1.94 kg when patients were changed from olanzapine to aripiprazole or quetiapine.[86] Another meta-analysisdetailedthatchangingtoaripiprazolebroughtaboutameanweightdecreaseof-2.55±1.5 kg.[87]More huge changes were noted when the switch was from olanzapine to aripiprazole. A RCT announced that changing from olanzapine, quetiapine or risperidone to aripiprazole brought about progress in metabolic parameters, however expanded the pace of suspension.[88] An industry-supported open-name expansion investigation of lurasidone revealed a little decrease in meanloadof-0.1kg. [89]Anotheropen-markstudydetailedthatchangingtoamisulpridebrought aboutweightdecreasewhencontrastedwiththebenchmarkgroup(7.8±6.67versus2.3±6.23).One year augmentation of three switch considers contrasting patients who changed from olanzapine, risperidone or FGA to ziprasidone noted huge decrease of weight for switchers from olanzapine and risperidone, yet not from FGAs.[90]

IMPACT OF WEIGHT GAIN ON COMPLAINCE:

SimilarlyasextrapyramidalresultsbringaboutthelplessconsistencewithFGAs,weightgain is a reason for treatment rebelliousness with SGAs. In any case, direct proof connecting weight gaintohelplessadherenceisinadequate.AnexaminationbyWeidenetalfoundthatpatientswho are fat are multiple times bound to stop drug due to weight gain than nonobese patients [91]. This was accounted for in the CATIE concentrate too, where more patients ceased olanzapine because of weight gain contrasted with different meds, regardless of olanzapine demonstrating the least in general stopping rate.[92,93] On the other hand, it has additionally been seen that weight gain is a marker of better reaction to antipsychotics and consistence can be relied upon to improve as a result.[94]Anewreportresearchingfactorsrelatedwithhelplessadherenceinpatientswithbipolar confusion revealed no distinction in adherence between weight groups.[95] The master agreement rulebyVelliganetaltakingdrugsadherenceofpatients withgenuinementalailmentdistinguished weight acquire as a conceivable factor prompting nonadherence.[96] The specialists prescribed tweakingintercessionstoaddresshelplessadherence. Weightgaininfluencespersonalsatisfaction and self-perspective on patients. Midriff perimeter and BMI anticipate low wellbeing related personalsatisfactioninpatientsonantipsychotics.[97]In theexaminationbyWeidenetal,abstract pain over weight gain was discovered to be the essential arbiter of resistance.[91] Weight gain, psychological results and sexual brokenness were fundamentally connected with helpless fulfillment and pain,

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

particularly in females.[98] A longitudinal subjective investigation meeting 63 first scene patients matured 14–35 years demonstrated that an adjustment in self-character followed with the change in actual appearance coming about because of weight gain.[99]There is proof that weight acquire in patients is of concern to guardians. A sent review to family members ofpatientswithschizophreniafoundthatthefamilyme mbersappraisedweightasthesecondmost tricky side effect.[100] The most problematic was sedation. Perkins conjectured that adherence to prescription is dictated by the patients' appraisal of advantages of treatment and dangers of backslideversustheexpensesoftreatment.Accordingl y,patientswhoseecostsmorethanbenefits expect intercessions to improve adherence.[101]These mediations ought to likewise incorporate proper methodologies to oversee AIWG. In spite of the proof that weight acquire expands horriblenessandmortalityanddecreasesadherence,si mply33%tohalfaresatisfactorilychecked forthemetabolicresultsofantipsychotics.[102]Intercess ionsthatbringaboutweightreductioncan improve personal satisfaction. A meta-analysis of 36 investigations of conduct or dietary mediations for stoutness detailed improvement in self-perception and wellbeing related personal satisfaction following weight loss.[103] However, another meta-analysis found no critical improvement in emotional wellness or by and large wellbeing related personal satisfaction after weightreduction,howeverunobtrusiveimprovementi nactualwellbeingwasreported.[104]Evans et al revealed huge enhancements in personal satisfaction in a patient accomplice on olanzapine acquainted with weight decrease procedures (intercession gathering), instead of the benchmark group (no weight decrease techniques introduced).[105]There is little proof that particular mediations to treat AIWG improve drug adherence or personal satisfaction. Studies from other patient populaces uphold the case that presentation of weight theexecutives systems will likewise improve prescription adherence. An investigation of patients with type 2 diabetes mellitus found that patients who experienced weight reduction had essentially better antidiabetic drug adherence contrastedwithpatientswithweightgain.[106]Awidesc opeoftechniqueshavebeenutilizedtooversee AIWG. The goal of this paper was to audit the current proof with respect to the viability of various pharmacologic and nonpharmacologic intercessions for AIWG.

II. DISCUSSION:

Practicallyallantipsychoticscauseweightgai n.Weightgainbuildsthedangerofmetabolic intricaciesandactualmedicalafflictionandcandiminis hconsistence.Afewtechniqueshavebeen attempted to decrease AIWG. Clinicians select antipsychotics dependent on patient inclination, viability and results profile. Haloperidol, lurasidone, ziprasidone, aripiprazole and amisulpiride convey lesser danger of weight gain, contrasted with different antipsychotics. In any case, danger of AIWG isn't the solitary factor which administers choice of antipsychotics. Clozapine, the drug with the most elevated danger of weight gain, is additionally the solitary antipsychotic so far authorized for treatment of resistant schizophrenia. Additionally, olanzapine which positionshigh asfarasadequacyconveyshigherdangerofweightgaint hanmostdifferentantipsychotics.Since the danger of weight gain has all the earmarks of being most elevated in the principal year of treatment, cautious checking and early intervention are the initial phase in overseeing AIWG.The accessible information portray a few techniques to attenuate AIWG. They are decreasing the portion, changing to an antipsychotic with less weight gain potential, adding drug adjuvants and nonpharmacologic interventions. Choosing powerful mediations is troublesome as most investigations have methodological limits. They are of brief term, going from half a month to a half year. Studies exploring techniques to forestall AIWG have included first-scene patients. Different examinations have explored treatment of AIWG. The reaction might be diverse in these twogatherings.Otherfrustratingcomponents,forexa mple,hereditaryhelplessnesstoweightgain, inactive ways of life and different meds that the patient is recommended will likewise impact the result. Nonpharmacologic intercessions are significant in the administration of AIWG. Dietary directing, practice mediations, psychological and social techniques seem, by all accounts, to be similarly compelling as individual and gathering treatments. All patients who are initiated on antipsychoticsoughttoberegularlyfurnishedwithwho lesomeadvisingandguidanceaboutasolid way of life. The individuals who put on weight ought to be selected organized program which screens the adherence of patients to the administration plan. Nonpharmacologic mediations give off an impression of being more powerful in patients treated with antipsychotics with a high inclination for weight gain. There is some proof that

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

consolidating way of life modification and metformin is more successful than either between vention alone.[107]Apart from a huge effect on cardio-metabolic danger factors, nonpharmacologic weight avoidance or decrease can possibly improve personal satisfaction, antipsychotic prescription adherence and in general guess of the ailment. Pharmacologic intercessions with proof of adequacy incorporate lessening the portion of the culpable prescription, changing to another antipsychotic with less capability of weight gain and adding an adjuvant to decrease weight. There is proof that changing to antipsychotics with lower danger of weight gain, for example, haloperidol, lurasidone, ziprasidone, aripiprazole and amisulpiride, brings about weight reduction. In any case, the danger of backslide and the probability of emergence of opposite results, for example, extrapyramidal results shouldbethought of. The other choice is to add an adjuvant. Metformin is the most broadly contemplated adjuvantandhasthebestproof.Prooffrommeta-analysisrecommendsameandistinctionof3kg over fake treatment in preliminaries which endured as long as 24 weeks. This compares toaround 1kg/m2reductionofBMI.[108]Weightreductionof$7% isconsideredclinicallysignificant.Proof showsthatmetforminbringsaboutclinicallyhugeweig htreductioninaboutalargeportionofthe patients.[109] Metformin might be more viable in forestalling AIWG in antipsychotic-credulous patients. Impacts of metformin past weight decrease, for example, glycemic control, are likewise a favorable position. Topiramate has less proof, however may bring about weight reduction of around 4 kg. It might have a helpful impact in patients with psychosis.[110]Although orlistat is affirmed by the Food and Drug Administration as a weight-lessening specialist, there is no proof that it is viable in AIWG. The proof with respect to other adjuvant drugs is deficient to suggest their utilization in clinical practice. The utilization of antipsychotics in kids and teenagers has expanded significantly in the course of recent many years. It is disturbing that youngsters and youths put on more weight than their grown-up partners, which inclines them to results of weight acquire for a long time. Weight acquire in kids has negative actual wellbeing just as emotional wellness outcomes. Kids and young people who are overweight can have issues with self- perception and confidence. Proof for metformin in kids isn't as powerful as ingrown-ups.

III. CONCLUSION:

In conclusion, This review shows that clozapine, olanzapine and quetiapine induce an increase of bodyweight to a higher amount and more frequently than risperidone., lifestyle modification and adding an adjuvant such as metformin or topiramate may help foresall and treat AIWG. Combination of interventions may be helpful. Interventions will have to be tailored according to individual needs. Forestalling weight gain in patients treated with antipsychotics ought to be viewed as a need.

REFERENCE:

[1]. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012;212:27–52

[2]. KapurS,RemingtonG.DopamineD(2)receptor sandtheirroleinatypicalantipsychoticaction: still necessary and may even be sufficient. Biol Psychiatry2001;50:873–83

[3]. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunc¬tive treatment with aripiprazoleonbodyweightandclinicalefficac yinschizophreniapatientstreatedwithclozapin e: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(8):1115–1125.

[4]. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry.2015;2(5):452–464.

[5]. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs.2011;25(12):1035–1059.

[6]. Ak M, Sezlev D, Sutcigil L, Akarsu S, Ozgen F, Yanik T. The investiga¬tion of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy. Psychoneuroendocrinology.2013;38(3):341–347.

[7]. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol.2006;20(1):75–79.

[8]. Lu ML, Wang TN, Lin TY, et al. Differential effects of olanzapine and clozapine on plasma levels of

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry. 2015;58:47–50.

[9]. Goncalves P, Araujo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol.2015;25(1):1–16.

[10]. Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ. Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J.2010;10(5):396–407.

[11]. Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug- related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418– 1437.

[12]. Rummel-Kluge C, Komossa K, Schwarz S,et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematicreview and meta-analysis. Schizophr Res.2010;123(2–3):225–233.

[13]. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA.2009;302(16):1765–1773.

[14]. BakM,FransenA,JanssenJ,vanOsJ,DrukkerM .Almostallantipsychot¬icsresultinweight gain: a meta-analysis. PLoS One.2014;9(4):e94112.

[15]. Vandenberghe F, Gholam-Rezaee M, Saigi-Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psycho¬tropic drug treatment. J Clin Psychiatry. 2015;76(11):e1417–e1423.

[16]. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic reviewofrandomized,placebocontrolledtrials andguidelinesforclinicalpractice.EurPsychiatry. 2011; 26(3):144–58.

[17]. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA.2009;302(16):1765–73

[18]. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab. 2006;8(2):125–35.

[19]. LambertMT,CopelandLA,SampsonN,Duffy SA.New-onsettype-2diabetesassociatedwith atypical antipsychotic medications. Prog Neuro- Psychopharmacol Biol Psychiatry. 2006;30(5):919–23.

[20]. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med.2004;19(12):12005.

[21]. Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L,Perez-Costillas L,GurpeguiM.Weightgainandincreaseofbody massindexamongchildrenandadolescentstreated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry.2013;22(8):457–79.

[22]. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol.2004;24(4):42936.

[23]. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first- episode psychosis: conclusions from a randomized, doubleblind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol.2008;28(1):27–31.

[24]. HaackS,SeeringerA,ThurmannPA,BeckerT, KirchheinerJ.Sex-specificdifferencesinside effects of psychotropic drugs: genes or gender? Pharmacogenomics.2009;10(9):1511–26.

[25]. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open- label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry. 2005;66(11):1468–76.

[26]. Pramyothin P, Khaodhiar L. Type 2 diabetes in children and adolescents on atypical antipsychotics. Curr Diab Rep.2015;15(8):53.

[27]. Cuerda C, Velasco C, Merchan-Naranjo J, Garcia-Peris P, Arango C. The effects of second- generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr.2014;68(2):146–52.

[28]. Bahra SM, Weidemann BJ, Castro AN, Walsh JW, deLeon O, Burnett CM, et

al.Risperidone- induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine. 2015;2(11):1725–34.

[29]. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol.2009;19(6):611–21.

[30]. ReekieJ,HoskingSP,PrakashC,KaoKT,JuonalaM,SabinMA.Theeffectofantidepressants and antipsychotics on weight gain in children and adolescents. Obes Rev.2015;16(7):566–80.

[31]. Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry.2016;73(3):247–59.

[32]. DeHertM,YuW,DetrauxJ,SweersK,vanWinkelR,CorrellCU.Bodyweightandmetabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs.2012;26(9):733–59.

[33]. Ngai YF, Sabatini P, Nguyen D, Davidson J, Chanoine JP, Devlin AM, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014;34(3):359–64.

[34]. ManuP,CorrellCU,WampersM,vanWinkelR, YuW,ShiffeldrimD,etal.Insulinsecretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013;143(2–3):358–62.

[35]. Kowalchuk C, Castellani LN, Chintoh A, Remington G, Giacca A, Hahn MK. Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol Endocrinol Metab. 2019;316(1):E1–15.

[36]. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol.2004;14(3):372–94.

[37]. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or suddencardiacdeath:anation-widecase-crossoverstudy.JAmHeartAssoc.2015;4(2):e001568.

[38]. Liu HC, Yang SY, Liao YT, Chen CC, Kuo CJ. Antipsychotic medications and risk of acute coronary syndrome in schizophrenia: a nested case-control study. PLoS One. 2016;11(9):e0163533.

[39]. Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry.2015;54(1):25–36.

[40]. Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol.2011;21(4):365–8.

[41]. Szmulewicz AG, Angriman F, Pedroso FE, Vazquez C, Martino DJ. Longterm antipsychotic use and major cardiovascular events: a retrospective cohort study. J Clin Psychiatry. 2017;78(8):e905–12.

[42]. Baptista T, Araujo de Baptista E, NMK Ng Ying Kin, et al.Obesity and related metabolic abnormalities during anti-psychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35:205-19

[43]. Baptista T, LaCruz A, Meza T, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiat 2001; 46:829-34

[44]. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti- psychotic with a novel mechanism of action, and risperidone 561-71 vs placebo in patients with schizophrenia and schizoaffective Arch Gen Psychiatry 2003; 60:681-90

[45]. BaiYM,LinCC,ChenJY,etal.Associationofinitialanti-psychoticresponsetoclozapineand long-term weight gain. Am J Psychiatry 2006; 163 (7):1276-9

[46]. BeasleyJrCM,TollefsonGD,TranPV.Safetyofolanzapine.JClinPsychiatry1997;58Suppl. 10: S13-7

[47]. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100

[48]. PerryPJ,ArgoTR,CarnahanRM,etal.Theassociationofweightgainandolanzapineplasma concentrations. J Clin Psychopharmacol

2005; 25 (3):250-4

[49]. CohenS,GlazewskiR,KhanS,etal.Weightgain withrisper-idoneamongpatientswithmental retardation: effect of calorie restriction. Clin Psychiatry 2001; 62 (2):114-6

[50]. Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psyobesity: chiatry 2003; 64 (3):316-20

[51]. Brecher M, Leong RW, Stening G, et al. Quetiapine and long term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68 (4): 597- 603

[52]. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29(4):303-19

[53]. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975-81

[54]. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents : a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10:259-68

[55]. KasperS,Mu¨ller-SpanhF.Reviewofquetiapineanditsclinicalapplicationsinschizophrenia. Exp Opin Pharmacother 2000;1:783-801

[56]. BuseJ,CavazzoniP,HornbuckleK,etal.Aretrospectivecohortstudyofdiabetesmellitusand antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56:164-70

[57]. AquilaR,EmanuelM.Interventionsforweightgaininadultstreatedwithnovelantipsychotics. Prim Care Companion J Clin Psychiatry2000;2:20–3.

[58]. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity.N Engl J Med2005;353:2111–20.

[59]. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM. Physical health monitoring of patients with schizophrenia. Am J Psychiatry2004;161:1–16.

[60]. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.

[61]. Morimoto T, Yamamoto Y, Mobarakeh J, et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav1999;67:679–83.

[62]. Atmaca M, Kuloglu M, Tezcan E, Ustandag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003;18:457–61.

[63]. Flors M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol2001;11:181–2.

[64]. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition2000;16:961–6.

[65]. Ko Y, Joe S, Jung IK, Kim S. Topiramate as an adjunct treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28:169–75.

[66]. Poyurovsky M, Pashmain A, Gil-Ad I, et al. Olanzapineinduced weight gain in patients with first episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. AmJ Psychiatry 2002;159:1058–60.

[67]. Henderson DC, Copeland PM, Daley TB, et al. A doubleblind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain. Am J Psychiatry2005;162:954–62.

[68]. JoffeG,TakalaP,TchoukhineE,etal.Orlistatinclozapineorolanzapinetreatedpatientswith overweight or obesity: a 16- week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry2008;69:706–11.

[69]. Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA. An exploration of the effect of modafinilonolanzapine-associatedweightgaininnormalhumansubjects[publishedonlineahead of print December 20, 2008]. Biol Psychiatry. Available from http://dx.doi.org/10.1016/j.biopsych.2008.10.037.

[70]. ZhouG,MyersR,LiY,etal.RoleofAMP-activatedproteinkinaseinmechanismofmetformin action. J Clin Invest.2001;108(8):1167–

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

1174.

[71]. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med.2004;256(1):1–14.

[72]. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss insubjects with obesity with type II non-insulin-dependent diabetes. Obes Res.1998;6(1):47–53.

[73]. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull.2014;40(6):1385–1403.

[74]. de Silva VA, Dayabandara M, Wijesundara H, et al. Metformin for treatment ofantipsychotic- induced weight gain in a South Asian popu¬lation with schizophrenia or schizoaffectivedisorder: a double blind, randomized, placebo controlled study. J Psychopharmacol. 2015;29(12):1255– 1261.

[75]. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry.1999;156(11):1686–1696.

[76]. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and toler¬ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.

[77]. Rummel-KlugeC,KomossaK,SchwarzS,etal.Head-to-headcom¬parisonsofmetabolicside effects of second generation antipsychotics in the treatment of schizophrenia: a systematicreview and meta-analysis. Schizophr Res.2010;123(2–3):225–233.

[78]. DeHertM,YuW,DetrauxJ,SweersK,vanWinkelR,CorrellCU.Bodyweightandmetabolicadverseeffectsofasenapine,iloperidone,lurasidoneandpaliperidoneinthetreatmentof schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–759.

[79]. BakM,FransenA,JanssenJ,vanOsJ,DrukkerM.Almostallantipsychot¬icsresultinweight gain: a meta-analysis. PLoS One.2014;9(4):e94112.

[80]. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic- induced weight gain in first-episode psy¬chosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry.2016;10(3):193–202.

[81]. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull.2007;33(3):654–656.

[82]. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull.2014;40(6):1385–1403.

[83]. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic reviewofrandomized,placebocontrolledtrials andguidelinesforclinicalpractice.EurPsychiatry. 2011;26(3):144–158.

[84]. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and toler¬ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.

[85]. Rummel-KlugeC,KomossaK,SchwarzS,etal.Head-to-headcom¬parisonsofmetabolicside effects of second generation antipsychotics in the treatment of schizophrenia: a systematicreview and meta-analysis. Schizophr Res.2010;123(2–3):225–233.

[86]. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev.2010;(12):CD006629.

[87]. Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: a meta-analysisinpatientssufferingfromschizophrenia.JObes.2011;2011.pii:898013.Epub2010Aug 25.

[88]. Stroup TS, McEvoy JP, Ring KD, et al; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olan¬zapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J

Psychiatry.2011;168(9):947–956.

[89]. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone,olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry.2013;74(5):507–515.

[90]. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res.2004;66(1):51–57.

[91]. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res.2004;66(1):51–57.

[92]. ManschreckTC,BoshesRA.TheCATIEschizophreniatrial:results,impact,controversy.Harv Rev Psychiatry.2007;15(5):245–258.

[93]. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE)Investigators.Effectivenessofantipsychoticdrugsinpatientswithchronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.

[94]. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry.2001;62(2):92–100.

[95]. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand.2013;127(1):23–33.

[96]. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 (Suppl 4):1–46; quiz47–48.

[97]. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull.2007;33(3):654–656.

[98]. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001;16(3):153–162.

[99]. Lester H, Marshall M, Jones P, et al. Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv.2011;62(8):882–887.

[100]. Angermeyer MC, Matschinger H. Neuroleptika und Lebensqualitat. Ergebnisse einer Patientenbefragung. [Neuroleptics and quality of life. A patient survey]. Psychiatr Prax. 2000;27(2):64–68.German.

[101]. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60 (Suppl 21):25–30.

[102]. Keller WR, Fischer BA, McMahon R, Meyer W, Blake M, Buchanan RW. Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis. 2014;202(1):6–12.

[103]. Lasikiewicz N, Myrissa K, Hoyland A, Lawton CL. Psychological benefits of weight loss following behavioural and/or dietary weight loss interventions. A systematic research review. Appetite.2014;72:123–137.

[104]. Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health-relatedqualityoflife:systematicreviewandmeta-analysisofrandomizedtrials.ObesRev. 2014;15(3):169–182.

[105]. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commencedonolanzapine:arandomizedcontrolledtrial.AustNZJPsychiatry.2005;39(6):479– 486.

[106]. Grandy S, Fox KM, Hardy E; SHIELD Study Group. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Curr Ther Res Clin Exp.2013;75:77–82.

[107]. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA.2008;299(2):185–193.

[108]. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 2 Mar-Apr 2022, pp: 134-147 www.ijprajournal.com ISSN: 2456-4494

Rev.2012;8(1):25–36.
[109]. deSilvaVA,DayabandaraM,WijesundaraH,et al.Metforminfortreatmentofantipsychotic-induced weight gain in a South Asian popu¬lation with schizophrenia or schizoaffectivedisorder: a double blind, randomized, placebo controlled study. J Psychopharmacol. 2015;29(12):1255– 1261.
[110]. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull.2014;40(6):1385–1403.

Table 1. Probability of weight gain with antipsychotics

Antipsychotic	Propensity to cause weight gain
Clozapine	High
Olanzapine	High (a,b)
Chlorpromazine	Moderate
Quetiapine	Moderate (b)
Risperidone	Moderate (b)
Paliperidone	Moderate
Aripiprazole	Low(c)
Amisulpride	Low(c)
Asenapine	Low
Haloperidol	Low(d)
Ziprasidone Lurasidone	Low (c,d) Low(d)

Notes: (a) Significantly greater increase in weight at .38 weeks, when compared with ,6 weeks period in both antipsychotic previously prescribed and naïve groups in the meta-analysis by Bak et al. (b) Significant weight gain seen in antipsychotic naïve group even ,6 weeks in the meta-analysis by Bak et al. (c) Weight neutral with duration of antipsychotic use in the meta-analysis by Bak et al. (d) No significant difference in weight when compared with placebo in multiple treatment meta- analysis by Leucht et al. Data from studies.